Interleukin-10 suppresses tissue factor expression in lipopolysaccharide- stimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERK1/2 pathway

Circulation Research

Volumn 97, Issue 4, 2005, Pages 305-313

  Kamimura, Motohiro ^a   Viedt, Christiane ^a   Dalpke, Alexander ^a   Rosenfeld, Michael E ^b   Mackman, Nigel ^c   Cohen, David M ^d   Blessing, Erwin ^a   Preusch, Michael ^a   Weber, Christian M ^a   Kreuzer, Jörg ^a   Katus, Hugo A ^a   Bea, Florian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Early growth response gene; Interleukin; Macrophages; Tissue factor

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; INTERLEUKIN 10; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; THROMBOPLASTIN; TRANSCRIPTION FACTOR ELK 1;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL TYPE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA BINDING; DNA FLANKING REGION; DNA SEQUENCE; DNA TRANSFECTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GEL MOBILITY SHIFT ASSAY; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REPORTER GENE; SERUM RESPONSIVE ELEMENT; SIGNAL TRANSDUCTION; THROMBOGENESIS; TRANSCRIPTION INITIATION;

ANIMALS; CELLS, CULTURED; DNA-BINDING PROTEINS; EARLY GROWTH RESPONSE PROTEIN 1; IMMEDIATE-EARLY PROTEINS; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MACROPHAGES; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RECEPTORS, IMMUNOLOGIC; REPRESSOR PROTEINS; RNA, MESSENGER; SERUM RESPONSE ELEMENT; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; THROMBOPLASTIN; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTORS;

EID: 24044544855     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000177893.24574.13     Document Type: Article

References (44)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001 23;104:503-516.
3. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res. 2002;53:313-325.
4. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci. U S A. 1989;86:2839-2843.
5. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, Stem D, Mackman N. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood. 2001;98:1429-1439.
6. Bea F, Puolakkainen MH, McMillen T, Hudson FN, Mackman N, Kuo CC, Campbell LA, Rosenfeld ME. Chlamydia pneumoniae induces tissue factor expression in mouse macrophages via activation of Egr-1 and the MEK-ERK1/2 pathway. Circ Res. 2003;92:394-401.
7. Gashler A, Sukhatme VP. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol. 1995;50:191-224.
8. Khachigian LM, Collins T. Early growth response factor 1: a pleiotropic mediator of inducible gene expression. J Mol Med. 1998;76:613-616.
9. McCaffrey TA, Fu C, Du B, Eksinar S, Kent KC, Bush HJ, Kreiger K, Rosengart T, Cybulsky MI, Silverman ES, Collins T. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. J Clin Invest. 2000;105:653-662.
10. Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis. 2003;167:187-194.
11. Silverman ES, Khachigian LM, Lindner V, Williams AJ, Collins T. Inducible PDGF A-chain transcription in smooth muscle cells is mediated by Egr-1 displacement of Sp1 and Sp3. Am J Physiol. 1997;273: H1415-H1426.
12. Khachigian LM, Lindner V, Williams AJ, Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science. 1996;271:1427-1431.
13. Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc Natl Acad Sci U S A. 1996;93:11831-11836.
14. Hu RM, Levin ER. Astrocyte growth is regulated by neuropeptides through Tis 8 and basic fibroblast growth factor. J Clin Invest. 1994;93:1820-1827.
15. Haas TL, Stitelman D, Davis SJ, Apte SS, Madri JA. Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem. 1999;274:22679-22685,
16. Maltzman JS, Carmen JA, Monroe JG. Transcriptional regulation of the Icam-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: role for transcription factor EGR1. J Exp Med. 1996;183:1747-1759.
17. Van SF, Pinsky DJ, Mackman N, Stern DM. Egr-1: is it always immediate and early? J Clin Invest. 2000;105:553-554.
18. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U. Induction of tissue factor expression in human endothelial cells via CD40 ligand is mediated by AP-1, NF-kB, and Egr-1. J Biol Chem. 2002;277:25032-25039.
19. Harja E, Bucciarelli LG, Lu Y, Stem DM, Zou YS, Schmidt AM, Yan SF. Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. Circ Res. 2004;94:333-339.
20. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM; CAPTURE Study Investigators. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003;107:2109-2114.
21. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 2001;104:746-749.
22. Potteaux S, Esposito B, van Oostrom O, Brun V, Ardouin P, Groux H, Tedgui A, Mallat Z. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:1474-1478.
23. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85:e17-e24.
24. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995;96:2304-2310.
25. Jungi TW, Brcic M, Eperon S, Albrecht S. Transforming growth factor-β and interleukin-10, but not interleukin-4, downregulate procoagulant activity and tissue factor expression in human monocyte-derived macrophages. Thromb Res. 1994;76:463-474.
26. Lindmark E, Tenno T, Chen J, Siegbahn A. IL-10 inhibits LPS-induced human monocyte tissue factor expression in whole blood. Br J Haematol. 1998;102;597-604.
27. Baetz A, Frey M, Heeg K, Dalpke AH. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J Biol Chem. 2004;279:54708-54715.
28. Schreiber E, Matthias P, Müller MM, Schaffner W. Rapid detection of octamer binding proteins with "mini-extracts", prepared from a small number of cells. Nucleic Acids Res. 1989;17:6419.
29. Cohen DM, Gullans SR, Chin WW. Urea inducibility of egr-1 in murine inner medullary collecting duct cells is mediated by the serum response element and adjacent Ets motifs. J Biol Chem. 1996;271:12903-12908.
30. Cui MZ, Parry GC, Oeth P, Larson H, Smith M, Huang RP, Adamson ED, Mackman N. Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and EGR-1. J Biol Chem. 1996;271:2731-2739.
31. Yoshioka T, Okada T, Maeda Y, Ikeda U, Shimpo M, Nomoto T, Takeuchi K, Nonaka-Sarukawa M, Ito T, Takahashi M, Matsushita T, Mizukami H, Hanazono Y, Kume A, Ookawara S, Kawano M, Ishibashi S, Shimada K, Ozawa K. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Ther. 2004;11:1772-1779.
32. Chu AJ, Prasad JK. Antagonism by IL-4 and IL-10 of endotoxin-induced tissue factor activation in monocytic THP-1 cells: activating role of CD14 ligation. J Surg Res. 1998;80:80-87.
33. Ramani M, Ollivier V, Khechai F, Vu T, Ternisien C, Bridey F, de Prost D. Interleukin-10 inhibits endotoxin-induced tissue factor mRNA production by human monocytes. FEBS Lett. 1993;334:114-116.
34. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002;277:32124-32132.
35. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem. 1999;274:31868-31874.
36. Clarke CJ, Hales A, Hunt A, Foxwell BM. IL-10-mediated suppression of TNF-alpha production is independent of its ability to inhibit NF kappa B activity. Eur J Immunol. 1998;28:1719-1726.
37. Denys A, Udalova IA, Smith C, Williams LM, Ciesielski CJ, Campbell J, Andrews C, Kwaitkowski D, Foxwell BM. Evidence for a dual mechanism for IL-10 suppression of TNF-alpha production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-kappa B in primary human macrophages. J Immunol. 2002;168:4837-4845.
38. Wu SQ, Minami T, Donovan DJ, Aird WC. The proximal serum response element in the Egr-1 promoter mediates response to thrombin in primary human endothelial cells. Blood. 2002;100:4454-4461.
39. Chai J, Tarnawski AS. Serum response factor: discovery, biochemistry, biological roles and implications for tissue injury healing. J Physiol Pharmacol. 2002;53:147-157.
40. Niiro H, Otsuka T, Ogami E, Yamaoka K, Nagano S, Akahoshi M, Nakashima H, Arinobu Y, Izuhara K, Niho Y. MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes. Biochem Biophys Res Commun. 1998;250:200-205.
41. Tamandl D, Bahrami M, Wessner B, Weigel G, Ploder M, Furst W, Roth E, Boltz-Nitulescu G, Spittler A. Modulation of toll-like receptor 4 expression on human monocytes by tumor necrosis factor and interleukin-6: tumor necrosis factor evokes lipopolysaccharide hyporesponsiveness, whereas interleukin-6 enhances lipopolysaccharide activity. Shock. 2003;20:224-229.
42. Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol. 2002;168:6404-6411.
43. Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, Ihle JN, Rutschman R, Murray PJ. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol. 2003;4:546-550.
44. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, Hirano T, Chien KR, Yoshimura A. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol. 2003;4:551-556.